Literature DB >> 2108815

Anticonvulsant therapy increases fentanyl requirements during anaesthesia for craniotomy.

R Tempelhoff1, P A Modica, E L Spitznagel.   

Abstract

This study was designed to determine whether patients receiving chronic anticonvulsant therapy demonstrate an altered requirement for fentanyl during anaesthesia. Sixty-one patients undergoing craniotomy were studied; 20 controls (MED = 0) who had never received anticonvulsants and 41 epileptics in whom therapeutic plasma concentrations of either one (MED = 1), two (MED = 2), or three (MED = 3) different anticonvulsants were documented. During anaesthesia with 60-70 per cent N2O in O2 and 0.2 per cent isoflurane, a maintenance dose (MD) of fentanyl was administered using a continuous variable-rate IV fentanyl infusion, supplemented by intermittent 50 micrograms IV boluses. In order to define the minimal dosage of fentanyl required, the MD was titrated according to increases or decreases in the heart rate and/or mean arterial pressure exceeding 15 per cent of baseline ward values. A progressively higher fentanyl MD was required in the epileptic patients (MED = 1-4.3 +/- 0.5 microgram.kg-1.hr-1; MED = 2-5.4 +/- 0.6; MED = 3-7.6 +/- 0.6) compared with the control MD (MED = 0-2.6 +/- 0.5) (P less than 0.001). These findings indicate that there appears to be a dose-effect relationship between the number of anticonvulsants received and the maintenance dose of fentanyl required during balanced anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2108815     DOI: 10.1007/BF03005584

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  17 in total

1.  Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery.

Authors:  M E Ausems; C C Hug; D R Stanski; A G Burm
Journal:  Anesthesiology       Date:  1986-10       Impact factor: 7.892

2.  Resistance to pancuronium in patients receiving carbamazepine.

Authors:  S Roth; Z Y Ebrahim
Journal:  Anesthesiology       Date:  1987-05       Impact factor: 7.892

3.  Anesthetic requirements and cardiovascular effects of fentanyl-oxygen and fentanyl-diazepam-oxygen anesthesia in man.

Authors:  T H Stanley; L R Webster
Journal:  Anesth Analg       Date:  1978 Jul-Aug       Impact factor: 5.108

4.  An animal model of halothane hepatotoxicity: roles of enzyme induction and hypoxia.

Authors:  G E McLain; I G Sipes; B R Brown
Journal:  Anesthesiology       Date:  1979-10       Impact factor: 7.892

5.  Use of continuous infusion versus intermittent bolus administration of fentanyl or ketamine during outpatient anesthesia.

Authors:  P F White
Journal:  Anesthesiology       Date:  1983-10       Impact factor: 7.892

6.  The action of anticonvulsant drugs on the firing of locus coeruleus neurons: selective, activating effect of carbamazepine.

Authors:  H R Olpe; R S Jones
Journal:  Eur J Pharmacol       Date:  1983-07-15       Impact factor: 4.432

7.  Effect of phenytoin on meperidine clearance and normeperidine formation.

Authors:  S M Pond; K M Kretschzmar
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

8.  Fentanyl-oxygen anaesthesia for coronary artery surgery: cardiovascular and antidiuretic hormone responses.

Authors:  T H Stanley; D M Philbin; C H Coggins
Journal:  Can Anaesth Soc J       Date:  1979-05

9.  The effect of population habits on side effects and narcotic requirements during high-dose fentanyl anaesthesia.

Authors:  T H Stanley; S de Lange
Journal:  Can Anaesth Soc J       Date:  1984-07

10.  The effect of phenobarbital on the metabolism of meperidine in normal volunteers.

Authors:  J E Stambaugh; I W Wainer; I Schwartz
Journal:  J Clin Pharmacol       Date:  1978-10       Impact factor: 3.126

View more
  12 in total

Review 1.  Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance.

Authors:  Sulpicio G Soriano; J A Jeevendra Martyn
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Safety considerations in the use of drug combinations during general anaesthesia.

Authors:  E S Ransom; R A Mueller
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

Review 3.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

4.  Comparison of fentanyl, sufentanil and alfentanil during awake craniotomy for epilepsy.

Authors:  E Gignac; P H Manninen; A W Gelb
Journal:  Can J Anaesth       Date:  1993-05       Impact factor: 5.063

Review 5.  Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  M Abel; W J Book; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

6.  Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl.

Authors:  Ala Nozari; Oluwaseun Akeju; Hooman Mirzakhani; Emad Eskandar; Zhijun Ma; Md Amin Hossain; Qingping Wang; David J Greenblatt; J A Jeevendra Martyn
Journal:  J Pharm Pharmacol       Date:  2019-02-21       Impact factor: 3.765

Review 7.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  Drug interactions of clinical significance with opioid analgesics.

Authors:  P M Maurer; R R Bartkowski
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

Review 9.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

Review 10.  Endpoints in pediatric pain studies.

Authors:  Monique van Dijk; Ilse Ceelie; Dick Tibboel
Journal:  Eur J Clin Pharmacol       Date:  2010-11-24       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.